Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, recently participated in two investor conferences to present updates on its lead drug candidate, CNM-Au8®. The company gave a fireside presentation at the 2024 Maxim Healthcare Virtual Summit on October 15 and will present at The ThinkEquity Conference 2024 on October 30 in New York. CNM-Au8® has shown promising results in restoring and protecting neurological function, offering hope for patients with amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. Clene is seeking an accelerated approval pathway for CNM-Au8 for ALS and is scheduled to meet with the FDA leadership in November. The company's focus on improving mitochondrial health and protecting neuronal function has garnered interest from investors, as CNM-Au8® targets a crucial aspect of neurodegenerative diseases. @clene_inc's participation in these conferences highlights its commitment to keeping investors informed about its progress and achievements. #biotechnology #neurodegenerative #investorconferences #clnn @clene_inc
NewsRamp™’s Post
More Relevant Posts
-
Clene Inc. (NASDAQ: CLNN), a biopharmaceutical company focused on improving mitochondrial health, recently presented its achievements at the H.C. Wainwright 26th Annual Global Investment Conference. The company highlighted its lead drug candidate, CNM-Au8, which has shown promise in restoring and protecting neurological function for neurodegenerative conditions. Clene Nanomedicine, Inc. is seeking FDA approval to file a new drug application for CNM-Au8, utilizing the accelerated approval pathway for the treatment of amyotrophic lateral sclerosis (ALS). The company's management presented recent results and plans for CNM-Au8 during the conference, held virtually from Sept. 9-11. 'We are excited about the potential of CNM-Au8 to provide new hope for patients with neurodegenerative diseases,' said Rob Etherington, President and CEO of Clene. 'The data so far is encouraging, and we look forward to advancing this promising therapeutic candidate.' #neurodegenerative #als #ms #biotech IBN (InvestorBrandNetwork)
Clene Showcases CNM-Au8 Progress at H.C. Wainwright Conference
newsramp.com
-
If you work with hepatocytes you know having a proper monolayer is essential. Now you can eliminate that challenge with plates of Opti-HEP seeded at the optimal density
We're excited to announce our new collaboration with Atelerix Ltd., enabling us to ship our iPSC hepatocyte (Opti-Heps) in vitro models to customers worldwide! Using Atelerix's hydrogel preservation technology, our models can now be stably transported, without the need for freezing or cryopreservation and without loss of function. This allows us to ship our models in assay-ready plates, not only enhancing the quality of our assays, but also saving researchers time by alleviating the need for thawing. Our Chief Business Officer, Heidi Kingdon Jones, reflected on the milestone: "By combining #DefiniGEN's innovative iPSC-derived hepatocyte models with Atelerix's revolutionary preservation technology, we are not only pushing the boundaries of scientific research but also contributing to a more sustainable and ethical approach in the biopharmaceutical industry." Read the full press release here:https://lnkd.in/exBXZVAk
-
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> Repair, Genevant ink deal worth up to $107M; 858 Therapeutics raises $50M >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #productmarketing #pharmaceutical #healthcare #pharma
Repair, Genevant ink deal worth up to $107M; 858 Therapeutics raises $50M
endpts.com
-
🚀 Are you attending #TIDES2024 in Hamburg, Germany, November 11-14? Let’s connect at booth #316! Our experts, Cátia Teixeira and Luísa Aguiar, are excited to share how our PurePep solutions can elevate your peptide projects to the next level. 💡 The peptide therapeutics landscape is rapidly evolving, driven by two major trends: ⭐ Innovative Screening Platforms: Chemical and display screening platforms are becoming the new standard for target-based drug development, enriching the preclinical pipeline significantly. ⭐ GLP-1 Analogs Success: The breakthrough in GLP-1 analogs for weight loss and obesity is transforming pharmaceutical interest in peptides, leading to high demand and a capacity crunch in synthesis. We’re here to help you navigate these changes—see you in Hamburg! #purepep #forpeptidescientists #synthesis #purification
-
-
Thoughts on this? >> Repair, Genevant ink deal worth up to $107M; 858 Therapeutics raises $50M >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #pharma #productmarketing #healthcare
Repair, Genevant ink deal worth up to $107M; 858 Therapeutics raises $50M
endpts.com
-
Discovery US 2024 By Oxford Global As recent technological and pharmacological advances tackle the previously ‘undruggable’, Discovery US returns to support the discovery of novel pharmaceutical modalities beyond the rule of five – including novel degraders, molecular glues, orally-available peptides and radioligands. Oxford Global's jam packed two-day agenda showcases the key platforms and technologies impacting early drug pipelines, from DNA-encoded libraries and phenotypic screening through to AI algorithms and organoid models. It brings together experts in target discovery and validation from across small & large biopharma organizations to discuss how the newest therapeutic paradigms can overcome historic challenges in drug development and provide optimized, novel drug candidates. Join the all star line up including: Abhijat Vatsyayan, Divya Kanichar, Fiona Mack, Giovanni Piedimonte, Graham T. Dempsey, Hong Cheng, Jason Ekert, Jennifer Caldwell Busby, Julie Owen, Martin Redhead, Paul Scola, Shelley Allen, for whats set to be a ground-breaking event!
-
📢 Exciting News from DelveInsight Business Research LLP! 🌟 Explore the latest advancements in the Spinal Muscular Atrophy (SMA) Pipeline with our comprehensive report! 🧬 The report provides in-depth insights into emerging therapies, key companies, and ongoing clinical trials that are shaping the future of #SMAtreatment. The leading #SpinalMuscularAtrophyCompanies such as Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics Inc. ANDROSCIENCE CORPORATION, Hanugen Therapeutics, Voyager Therapeutics, Inc., Roche, Catalyst Pharmaceuticals, Inc., NMD Pharma A/S, Biohaven Pharmaceuticals, CANbridge Pharmaceuticals Inc. Aurimed Pharma, Exicure, Amylon Therapeutics Amniotics AB, and others. Stay ahead in the evolving #SMAlandscape! 🔬 Get More Insights @ https://lnkd.in/dJH9G75r #SpinalMuscularAtrophy #SMA #PharmaPipeline #Biotech #HealthcareResearch #DelveInsight #ClinicalTrials #SMAAwareness #PharmaUpdates
-
-
Exciting advancements in Alzheimer’s research! Coya Therapeutics, Inc. announced positive results from a Phase 2 study on low-dose interleukin-2 (LD IL-2) presented at CTAD24 in Madrid. Led by renowned experts, this trial highlights the potential of LD IL-2 to enhance regulatory T cell function in 𝐀𝐥𝐳𝐡𝐞𝐢𝐦𝐞𝐫’𝐬 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬. 𝐋𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐨𝐮𝐫 𝐜𝐨𝐦𝐦𝐢𝐭𝐦𝐞𝐧𝐭 𝐭𝐨 𝐚𝐝𝐯𝐚𝐧𝐜𝐢𝐧𝐠 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 𝐟𝐨𝐫 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐢𝐧 𝐧𝐞𝐞𝐝. 🔗 https://lnkd.in/gEPexeJD #Alzheimers #ClinicalTrials #Innovation #TregFunction #Biotechnology #CoyaTherapeutics #Healthcare #Research #NeurodegenerativeDiseases #CTAD24 #Pharmaceuticals #PatientCare #LifeSciences #DrugDevelopment #MedicalResearch
-
-
Thoughts on this? >> Gilead's Kite uncouples from Fosun in China as Yescarta faces coverage obstacles >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #productmarketing #biotech #pharma #healthcare
Gilead's Kite uncouples from Fosun in China as Yescarta faces coverage obstacles
endpts.com
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> Gilead's Kite uncouples from Fosun in China as Yescarta faces coverage obstacles >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #healthcare #biotech #productmarketing
Gilead's Kite uncouples from Fosun in China as Yescarta faces coverage obstacles
endpts.com
